A baby born deaf can hear again due to a groundbreaking gene therapy trial when she was eleven months old.
Gene editing companies in China are restarting clinical trials in blood, liver, and eye diseases.
61% of HCPs have a favourable view of pharma companies but they have very mixed feelings about corporate campaigns and messaging.
Boehringer Ingelheim and OSE Immunotherapeutics are expanding their partnership to include two clinical-stage oncology programs in cardio-renal metabolic disease and a third preclinical cancer project.
Novo Nordisk is now looking beyond weight loss and diabetes to expand into new illnesses like liver disease, chronic kidney disease, and Alzheimer's.
AstraZeneca says it will continue to be a conduit for sharing Chinese innovations with the rest of the world and will establish a dedicated supply chain.
Merck KaGA's North America Life Sciences division, MilliporeSigma, helped expose a multimillion dollar scheme to divert biochemical products to China.
AstraZeneca has set an ambitious $80 billion revenue goal for 2030 and they announce they will be focusing on "difficult to copy" therapies.
Scientists have harnessed cells to create new types of materials that can grow and repair themselves, applications could one day include biomanufacturing and pharma.
CalmStrips are portable fidget strips for individuals who require sensory stimulation to calm things like anxiety, ADHD, and more.
Ipsen uses TikTok trends and influencers to raise awareness of rare disease fibrodysplasia ossificans progressiva (FOP).
Celltrion has partnered with British reality star Mollie Pearce on new Crohn's and Colitus campaign.
%402x.svg){kind=icon}
.png)
%402x.svg){kind=icon}
